A Phase 2, Open-Label Study to Evaluate the Safety, Microbiology and Pharmacokinetics of C16G2 Administered in Single or Multiple Oral Gel Doses to Healthy Adult Subjects
Phase of Trial: Phase II
Latest Information Update: 26 Jul 2019
Price : $35 *
At a glance
- Drugs C 16G2 (Primary)
- Indications Dental caries
- Focus Adverse reactions
- Sponsors Armata Pharmaceuticals; C3 Jian
- 15 Jul 2015 According to an C3 Jian media release, company announced that it has preliminary data from this trial.
- 13 Jul 2015 Status changed from active, no longer recruiting to completed according to an C3 Jian media release.
- 26 May 2015 Planned End Date changed from 1 Apr 2015 to 1 Aug 2015 as reported by ClinicalTrials.gov record.